logo-loader
viewOptiBiotix Health PLC

License agreement for LPLDL®

/**/ sub{font-size:80%}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .aj{size:595.3pt 841.9pt;margin:90.25pt 2.0cm 35.45pt 2.0cm;}div.aj{}p.cl{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}span.ci{font-size:10.0pt}p.cm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: center}p.cn{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}span.cg{font-size:12.0pt}p.co{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;text-autospace:none}span.ce{letter-spacing: -.05pt}span.cd{letter-spacing:-.1pt} span.cp{letter-spacing:1.85pt}span.cb{letter-spacing:-.05pt}span.ca{letter-spacing:-.15pt}span.cq{letter-spacing:1.9pt}span.by{letter-spacing: -.15pt}span.cr{letter-spacing: 1.85pt}span.cs{letter-spacing:1.8pt}span.ct{letter-spacing:2.0pt}span.cu{letter-spacing: .1pt}span.bt{letter-spacing:.1pt} span.ag{}span.br{color:#212529}span.bq{color:black}span.bp{color:black; letter-spacing:.05pt}span.bo{letter-spacing:.05pt}span.bn{letter-spacing:.15pt}span.bm{letter-spacing:-.2pt}span.bl{}span.bk{letter-spacing:.6pt}span.bj{letter-spacing:.65pt} span.bi{letter-spacing:.75pt}span.bh{letter-spacing:.55pt}span.bg{letter-spacing: .6pt}span.bf{letter-spacing:.55pt}span.be{letter-spacing: -.1pt}p.cv{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; margin-bottom: 0cm; text-align: justify}p.cw{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;vertical-align:baseline}p.cx{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.bb{font-size:10.0pt; color:black}p.cy{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal} table.cz{margin-left:-5.4pt;border-collapse:collapse}td.ax{width:334.1pt;padding:0cm 5.4pt 0cm 5.4pt}p.da{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}td.av{width:126.2pt;padding:0cm 5.4pt 0cm 5.4pt}p.db{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}p.dc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: right}p.dd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt}td.as{width:228.25pt;padding:0cm 5.4pt 0cm 5.4pt}td.ar{width:232.05pt;padding:0cm 5.4pt 0cm 5.4pt}td.aq{border:none} p.an{font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify}span.ao{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.ak{margin:0cm;margin-bottom:.0001pt;text-align:justify}span.am{font-size:11.0pt;font-family: "Calibri","sans-serif"}span.al{font-size: 11.0pt;font-family:"Calibri","sans-serif"} /**/
RNS Number : 0835Y
OptiBiotix Health PLC
07 May 2019
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

License agreement for LPLDL® in personalised nutrition applications

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has signed a license agreement with Instituto Español de Nutrición Personalizada, S.A. ("IENP") for the use of Lactobacillus plantarum ("LPLDL®") in personalised food supplements in Spain.

 

The agreement grants IENP non-exclusive rights to manufacture and market food supplements containing OptiBiotix's cholesterol and blood pressure-reducing probiotic strain LPLDL® in Spain for a period of three years. IENP is the precision nutrition branch of CAPSA Food, one of the largest food conglomerates in Spain, owner of leading dairy brands such as Central Lechera Asturiana and Larsa, with annual revenues of over €700m. In 2017, they were awarded 'Leading company in the Food Sector' with the ORO +500 SEAL of European Excellence and the Reptrak first prize for the company with the best reputation in Spain by the Reputation Institute (see https://www.capsafood.com/company/awards)

 

IENP have developed an innovative genomic test to analyse the gut microbiome, the bacteria living in the intestine, to detect imbalances which may potentially lead to different health conditions. Based on results, customers are placed on different, targeted food supplement regimens to take their microbiome composition back to healthy. IENP have developed COL-15, a microbiome-modulating food supplement commercialised under the "39ytú" brand. IENP will use their extensive network to market the product in supermarkets, department stores, pharmacies, and online across Spain.

 

Personalised nutrition is a nascent field which holds the promise to revolutionise the way food, health and wellness are conceived. According to Reseach And Markets (2018), the global market for personalised nutrition is expected to grow by CAGR ca. 10% to USD$50bn by 2025, with food supplements its fastest-growing segment.

 

Dr. Luis Gosálbez, Business Development Director of OptiBiotix, commented: "We are delighted to enter the field of personalised and precision nutrition, one of the fastest-growing and highest-value sectors within the food industry. We chose IENP due to its industry reputation, decades of experience in the Spanish food market, and its ability to rapidly launch products and build sales. Within two years of launch, we now have products being sold by numerous partners in over 30 countries around the world. This builds revenues and increases the value of our trademarked and patented assets, like LPLDL®, as it grows into a global brand. We see this agreement as another step to growing revenues, market presence, and brand value of LPLDL®, the 'Intel' inside a wide range of products in consumer and pharmaceutical markets around the world."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)


Liam Murray / Jo Turner

Tel: 020 7213 0880

 

finnCap (Broker)


Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)

Camille Gochez (Corporate Broking)

 

Tel: 020 7220 0500

 

Walbrook PR Ltd

 

Tel: 020 7933 8780 or [email protected]

Anna Dunphy

Mob: 07876 741 001

 

 

About OptiBiotix - www.optibiotix.com 

 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGRBSGDURBGBGCX

Quick facts: OptiBiotix Health PLC

Price: 61.5

Market: AIM
Market Cap: £52.55 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

OptiBiotix's Stephen O'Hara hails new safety status for LPLDL and recent awards

OptiBiotix Health PLC’s (LON:OPTI) Stephen O'Hara speaks to Proactive London's Andrew Scott soon after the news its LPLDL probiotic had been granted ‘generally recognised as safe’ (GRAS) status by the US Food and Drug Administration (FDA). Its subsidiary, ProBiotix Health Ltd, received the...

3 weeks ago